400 related articles for article (PubMed ID: 18855156)
21. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer.
Park IJ; Choi GS; Jun SH
Anticancer Res; 2009 Oct; 29(10):4303-8. PubMed ID: 19846991
[TBL] [Abstract][Full Text] [Related]
22. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
Akdoğan M; Parlak E; Kayhan B; Balk M; Saydam G; Sahin B
Turk J Gastroenterol; 2003 Sep; 14(3):181-4. PubMed ID: 14655062
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer.
Yakabe T; Nakafusa Y; Sumi K; Miyoshi A; Kitajima Y; Sato S; Noshiro H; Miyazaki K
Ann Surg Oncol; 2010 Sep; 17(9):2349-56. PubMed ID: 20217258
[TBL] [Abstract][Full Text] [Related]
24. Slope analysis of CA19-9 and CEA for predicting recurrence in colorectal cancer patients.
Nakayama T; Watanabe M; Teramoto T; Kitajima M
Anticancer Res; 1997; 17(2B):1379-82. PubMed ID: 9137502
[TBL] [Abstract][Full Text] [Related]
25. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
26. Carcinoembryonic antigen messenger RNA expression in blood can predict relapse in gastric cancer.
Ishigami S; Sakamoto A; Uenosono Y; Nakajo A; Okumura H; Matsumoto M; Setoyama T; Arigami T; Uchikado Y; Arima H; Natsugoe S; Aikou T
J Surg Res; 2008 Aug; 148(2):205-9. PubMed ID: 17936797
[TBL] [Abstract][Full Text] [Related]
27. [Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients].
Grotowski M; Maruszyński M; Piechota W
Pol Merkur Lekarski; 2001 Dec; 11(66):476-9. PubMed ID: 11899841
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer.
Li Y; Yang Y; Lu M; Shen L
Hepatogastroenterology; 2011; 58(112):2166-70. PubMed ID: 22024091
[TBL] [Abstract][Full Text] [Related]
29. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.
Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H
Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496
[TBL] [Abstract][Full Text] [Related]
30. [Changes in tumor markers CEA, Ca 19-9 and Ca 125 in monitoring of response to chemotherapy in elderly patients with advanced gastric cancer].
Caponetti R; Caponetti T; Vici P
Clin Ter; 2002; 153(6):373-5. PubMed ID: 12645392
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer.
Kim JH; Jun KH; Jung H; Park IS; Chin HM
Hepatogastroenterology; 2014 May; 61(131):863-9. PubMed ID: 26176088
[TBL] [Abstract][Full Text] [Related]
32. Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer.
Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Toyokawa T; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K
Anticancer Res; 2014 Jul; 34(7):3753-8. PubMed ID: 24982398
[TBL] [Abstract][Full Text] [Related]
33. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Petrioli R; Licchetta A; Roviello G; Pascucci A; Francini E; Bargagli G; Conca R; Miano ST; Marzocca G; Francini G;
Cancer Invest; 2012 Jan; 30(1):65-71. PubMed ID: 22236191
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer.
Forones NM; Mandowsky SV; Lourenço LG
Hepatogastroenterology; 2001; 48(40):1199-201. PubMed ID: 11490833
[TBL] [Abstract][Full Text] [Related]
35. Better outcomes by monitoring tumour dynamics using sensitive tumour markers in patients with recurrent gastric cancer.
Komatsu S; Ichikawa D; Nishimura Y; Kubota T; Okamoto K; Shiozaki A; Fujiwara H; Konishi H; Murayama Y; Kuriu Y; Ikoma H; Nakanishi M; Otsuji E
Anticancer Res; 2013 Apr; 33(4):1621-7. PubMed ID: 23564806
[TBL] [Abstract][Full Text] [Related]
36. Carcinoembryonic antigen and CA19-9: implications of quantitative marker measurement in tissues for prognosis of colorectal cancer.
Gebauer G; Müller-Ruchholtz W
Cancer Detect Prev; 2001; 25(4):344-51. PubMed ID: 11531011
[TBL] [Abstract][Full Text] [Related]
37. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H;
Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526
[TBL] [Abstract][Full Text] [Related]
38. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells.
Jiang J; Xu N; Wu C; Deng H; Lu M; Li M; Xu B; Wu J; Wang R; Xu J; Nilsson-Ehle P
Anticancer Res; 2006; 26(3B):2237-42. PubMed ID: 16821594
[TBL] [Abstract][Full Text] [Related]
39. Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer.
Abbas M; Ahmed A; Khan GJ; Baig MMFA; Naveed M; Mikrani R; Cao T; Naeem S; Shi M; Dingding C
Curr Probl Cancer; 2019 Feb; 43(1):5-17. PubMed ID: 30172422
[TBL] [Abstract][Full Text] [Related]
40. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
